List of Contributors xii
Dedications xxvi
Scientists Honored for Pioneering Research xxix
Preface xxxv
Acknowledgments xxxvi
I. EPIDEMIOLOGY AND RISK FACTORS 1
1. The Transition from Normal Functioning to Dementia in the
Aging Population 3
Laura Fratiglioni, Brent Small, Bengt Winblad and Lars Bäckman
2. Epidemiology of Alzheimer’s Disease and Dementia: Advances
and Challenges 11
Robert Katzman
3. Epidemiology of Dementia in Down’s Syndrome 23
Nicole Schupf
II. GENETICS 31
4. A Genomic Search for Alzheimer’s Disease Genes 33
Jonathan L. Haines, L. Renee Bailey, Janet M. Grubber, Dale Hedges,
Jenifer L. Hall, Sandra West, Leonard Santoro, Beth Kemmerer, Anne
M. Saunders, Allen D. Roses, Gary W. Small, William K. Scott, P.
Michael Conneally, Jeffery M. Vance and Margaret A.
Pericak-Vance
5. Candidate Genes Showing No Evidence of Association with
Alzheimer’s Disease: Results of the NIMH-AD Genetics Initiative
45
Lars Bertram, Deborah Blacker, Adam S. Crystal, Jennifer Jones,
Devon Keeney, Laura A. MacKenzie-Ingano, Kristina Mullin, Sanjay
Basu, Stephen Yhu, Melvin McInnis, Rodney C. P. Go, Aleister J.
Saunders and Rudolph E. Tanzi
6. Familial Alzheimer’s Disease with Spastic Paraparesis
Associated with a Mutation at Codon 261 of the Presenilin 1 Gene
53
Martin R. Farlow, Jill R. Murrell, Frederick W. Unverzagt, Michael
Phillips, Masaki Takao, Christine Hulette and Bernardino Ghetti
7. Genetic Analysis of the Presenilin Pathway in Drosophila
61
Izhar Livne-Bar and Gabrielle L. Boulianne
8. Molecular Genetics and Transgenic Modeling of the Tauopathies
71
Jada Lewis, Matt Baker, Marjon Van Slegtenhorst and Mike Hutton
9. Regulation of Four-repeat tau Expression: Interactions
between Exon and Intron Splicing Regulatory Sequences 87
Ian D’Souza and Gerard D. Schellenberg
III. DIAGNOSIS AND CLINICAL COURSE 97
10. Preclinical Prediction of AD: Relation Between
Neuropsychological and Neuroimaging Findings 99
Marilyn S. Albert, Ronald J. Killiany, Keith Johnson, Rudolph E.
Tanzi and Kenneth Jones
11. Neuropsychological Detection of Preclinical Alzheimer’s
Disease: Results of a Neuropathological Series of ‘Normal’ Controls
111
Kathleen A. Welsh-Bohmer, Christine Hulette, Donald Schmechel,
James Burke and Ann Saunders
12. Potentially Reversible Conditions in Memory Clinic Patients
123
Anne-Mette Hejl, Peter Høgh and Gunhild Waldemar
13. The Alzheimer’s Disease Centers’ Neuropsychological Database
Initiative: A Resource for Alzheimer’s Disease Prevention Trials
129
Michael Grundman, Hyun T. Kim, David Salmon, Martha Storandt, Glenn
Smith, Steven Ferris, Richard Mohs, Jason Brandt, Rachelle Doody,
Kathleen Welsh-Bohmer, Judith Saxton, Kathy Saine, Frederick
Schmitt, Paula Ogrocki, Nancy Johnson, Diane Howieson, Michelle
Papka, Joanne Green, Anthony Gamst, Walter Kukull and Leon J. Thal,
for the Alzheimer’s Disease Centers’ Neuropsychological Database
Initiative
14. Mild Cognitive Impairment: Transition from Aging to
Alzheimer’s Disease 141
Ronald C. Petersen
15. Brain Functional Imaging in Early and Preclinical
Alzheimer’s Disease 153
Agneta Nordberg, Vesna Jelic, Eva Arnáiz, Bengt Långström and Ove
Almkvist
16. Amyloid, PHF-tau, Ubiquitin and Synaptic Markers in the
Progression of Alzheimer’s Disease: Immunochemical Analyses of
Frontal Cortex from Prospectively Studied Elderly Humans 165
D. S. Wang, E. Cochran, D. Bennett, E. Mufson, C. Eckman and D. W.
Dickson
17. Imaging the Consequences of Alzheimer’s Disease Pathology
181
Yaakov Stern and Scott Small
18. Influence of apoE Genotype and PET Brain Imaging on
Preclinical Prediction of Alzheimer’s Disease 193
Gary W. Small, Linda M. Ercoli, Daniel H.S. Silverman, S.-C. Huang,
Susan Y. Bookheimer, Helen Lavretsky, Karen Miller, Prabha
Siddarth, John C. Mazziotta, Ann M. Saunders, Margaret A.
Pericak-Vance, Allen D. Roses, Jorge R. Barrio and Michael E.
Phelps
19. Overview of Vascular Dementia 205
William R. Markesbery
20. Clinical and Imaging Characteristics of Vascular Dementia in
a Memory Clinic 219
F. Pasquier, X. Douay, C. Delmaire, F. Lebert and J. P. Pruvo
21. MRI of Entorhinal Cortex and Hippocampus in Alzheimer’s
Disease, Subcortical Ischemic Vascular Dementia and Mixed Dementia
229
N. Schuff, A. T. Du, D. Amend, Y. Y. Hsu, M. P. Laakso, W. Jagust,
H. C. Chui and M. W. Weiner
22. Olfactory Function and Event-related Potentials in
Alzheimer’s Disease 237
Claire Murphy and Charlie D. Morgan
23. Phenotypic Differences in Cholinergic Markers within the
Nucleus Basalis in Individuals with Mild Cognitive Impairment
253
Elliott J. Mufson, Michele Gilmor, Shuang Y. Ma, Alan I. Levey and
Jeffrey H. Kordower
24. Evaluating CNS Biomarkers for Alzheimer’s Disease 265
John H. Growdon
25. CSF Markers for Early Alzheimer’s Disease 275
Kaj Blennow, Pia Davidsson and Eugeen Vanmechelen
26. CSF-Phospho-tau (181P) as a Promising Marker for
Discriminating Alzheimer’s Disease from Dementia with Lewy Bodies
285
E. Vanmechelen, E. Van Kerschaver, K. Blennow, P. P. De Deyn, D.
Galasko, L. Parnetti, C. J. M. Sindic, H. Arai, M. Riemenschneider,
H. Hampel, H. Pottel, A. Valgaeren, F. Hulstaert and H.
Vanderstichele
27. Increased Levels of a Minor Glycoform of
Acetylcholinesterase in Alzheimer’s Disease Brain and Cerebrospinal
Fluid 293
Javier Sáez-Valero, Su San Mok, Lisa Fodero, Alberto Marcos,
Maria-Sagrario Barquero, Catriona McLean and David H. Small
28. Plasma b-Amyloid as a Surrogate Genetic Marker in Late-onset
Alzheimer’s Disease 303
Nilufer Ertekin Taner, Neill Graff-Radford, Linda H. Younkin,
Christopher Eckman, Jennifer Adamson, Daniel J. Schaid, John
Blangero, Michael Hutton and Steven G. Younkin
29. Levels of Total and Deposited Ab are Correlated with
Dementia 311
S. Parvathy, J. Naslund, V. Haroutunian and J. D. Buxbaum
30. What Should We Tell Patients Attending a Memory Disorders
Clinic About Their Diagnosis? 319
Conor P. Maguire and Rebecca M. Slinn
IV. MECHANISMS OF NEURODEGENERATION 329
31. Innate Immunity, Autotoxicity and Degenerative Neurologies
331
Patrick L. McGeer, Koju Yasojima and Edith G. McGeer
32. Neuroinflammatory Responses in the Alzheimer’s Disease Brain
Promote the Oxidative Post-translational Modification of Amyloid
Deposits 341
Craig S. Atwood, Xudong Huang, Robert D. Moir, Mark A. Smith,
Rudolph E. Tanzi, Alex E. Roher, Ashley I. Bush and George
Perry
33. Plasma Antioxidants and Oxidative DNA Damage in Lymphocytes
from Normal Aged People and Alzheimer’s Disease Patients 363
Patrizia Mecocci, Maria Cristina Polidori, Tiziana Ingegni, Paola
Mattioli, Antonio Cherubini, Marco Catani, Roberta Cecchetti and
Umberto Senin
34. Oxidative Damage and Antioxidant Responses in Alzheimer’s
Disease 371
George Perry, Akihiko Nunomura, Jesus Avila, Mar Perez, Catherine
A. Rottkamp, Craig S. Atwood, Xiongwei Zhu, Gjumrakch Aliev, Adam
D. Cash and Mark A. Smith
35. Cyclooxygenase (COX)-2 and Clinical Progression of
Alzheimer’s Disease Dementia: Implications in the Role of Neuronal
COX-2 in Cell Cycle 379
Giulio Maria Pasinetti
36. Parallels between the Redox Properties and Toxicity of Ab in
Alzheimer’s Disease and Mutant Cu/Zn-SOD in Familial Amyotrophic
Lateral Sclerosis 393
Ashley I. Bush
37. b-Amyloid Toxicity: Diverse Biological Activities Drive
Multiple Cellular Mechanisms 407
C. W. Cotman, L. Tong, A. Anderson, D. Cribbs and J. Su
38. Mechanisms of Ab Production and Ab Degradation: Routes to
the Treatment of Alzheimer’s Disease 421
D. J. Selkoe, W. Xia, W. T. Kimberly, K. Vekrellis, D. Walsh, W. P.
Esler and M. S. Wolfe
39. A High Fat, High Cholesterol Diet Accelerates b-Amyloid
Accumulation in the CNS of a Transgenic Mouse Model of Alzheimer’s
Disease 433
Lorenzo M. Refolo, Brian Malester, John LaFrancois, Tara
Bryant-Thomas, Rong Wang, G. Stephen Tint, Kumar Sambamurti, Karen
Duff and Miguel A. Pappolla
40. Electron Microscopy and X-ray Diffraction Studies further
Confirm the Efficacy of PTI-00703TM1 (Cat’s Claw Derivative) as a
Potential Inhibitor of Alzheimer’s b-Amyloid Protein
Fibrillogenesis 449
Gerardo M. Castillo, Daniel A. Kirschner, Ann G. Yee and Alan D.
Snow
41. Accelerated Ab Generation in a Cell Model of Alzheimer’s
Disease-related Endosomal–Lysosomal System Upregulation 461
Paul M. Mathews, Carolyn B. Guerra, Ying Jiang, Benjamin H. Kao,
Ravi Dinakar, Pankaj Mehta, Anne M. Cataldo and Ralph A. Nixon
42. The Amyloid Precursor Protein V717I Mutation Increases
Susceptibility to Cell Death in a Cholesterol-dependent Manner
469
Luigi Puglielli, Laura A. MacKenzie Ingano, Rudolph E. Tanzi and
Dora M. Kovacs
43. Intracellular and Secreted Ab42/40 Ratios Are Differently
Influenced by APP Mutations 479
Heike S. Grimm, Stefan F. Lichtenthaler, Konrad Beyreuther and
Tobias Hartmann
44. Familial British Dementia 487
Jorge Ghiso, Tamas Révész, Agueda Rostagno, Ruben Vidal, Gordon
Plant and Blas Frangione
45. Cellular Metabolism of Familial British Dementia-associated
BRI-L 495
Seong-Hun Kim and Sangram S. Sisodia
46. A Decamer Duplication in the BRI Gene Originates a de novo
Amyloid Peptide that Causes Dementia in a Danish Kindred 507
Ruben G. Vidal, Tamas Révész, Agueda Rostagno, Toke Bek, Hans
Braendgaard, Gordon Plant, Jorge Ghiso and Blas Frangione
47. Familial Alzheimer’s Disease-linked Mutant Presenilins
Attenuate Capacitative Calcium Entry 515
Isaac Cheng, Andrew S. Yoo, Rudolph E. Tanzi and Tae-Wan Kim
48. Presenilin-1 Is a Regulatory Component of the Cadherin Cell
Adhesion Complex: Implications for Alzheimer’s Disease 521
Anastasio Georgakopoulos, Philippe Marambaud, Nikolaos K. Robakis
and Lia Baki
49. Presenilins and Notch Signaling Pathway 531
Weihong Song and Bruce A. Yankner
50. Functional Consequences of the Association of PS1 with
b-Catenin 541
Salvador Soriano, David E. Kang, Nathalie Chevallier, Hui Zheng and
Edward H. Koo
51. A Novel Protease Active Site Motif Conserved in Presenilins
and Polytopic Bacterial Aspartyl Proteases? 549
Harald Steiner and Christian Haass
52. The Unfolded Protein Response-mediated Upregulation of BiP
and CHOP Is not Affected by Presenilin Expression 559
Naoyuki Sato and Gopal Thinakaran
53. Mechanisms of a-Synuclein and NAC Fibrillogenesis 569
Makoto Hashimoto, Edward Rockenstein, Takato Takenouchi, Margaret
Mallory and Eliezer Masliah
54. Neurofibrillary Degeneration: Patterns of Tau Isoform
Expression 587
André Delacourte
55. Phosphorylation, Microtubule Binding and Aggregation of Tau
Protein in Alzheimer’s Disease 601
Jesús Ávila, José J. Lucas, Filip Lim, Mar Pérez, Félix Hernández,
Montserrat Arrasate, Rosario Armas Portela, Elsa Champion, George
Perry, Mark A. Smith and Javier Díaz Nido
56. Phosphorylation of Protein Tau and Rescue of Protein
Tau-induced Axonopathy by GSK-3b in GSK-3b6htau40 Double Transgenic
Mice 609
Kurt Spittaels, Chris Van den Haute, Jo Van Dorpe, Hugo Geerts and
Fred Van Leuven
57. Pathogenic Implication of Altered Tau Properties Caused by
FTDP-17 Mutations 621
P. Nacharaju, S. Yen, M. DeTure, C. Easson, M. Hutton and S.-H.
Yen
58. A Hexapeptide Motif (306VQIVYK311)-forming b Structure
Induces the Aggregation of Tau Protein to Paired Helical Filaments
631
M. von Bergen, J. Biernat, E.-M. Mandelkow and Eckhard
Mandelkow
V. ANIMAL AND CELLULAR MODELS 641
59. Formation of Neurofibrillary Tangles in Mouse Brain 643
Akihiko Takashima and Kentaro Tanemura
60. Inducible Transgenic Expression of Wild-type tau in H4
Neuroglioma Cells 651
Michael DeTure, Li-Wen Ko, Colin Easson, Mike Hutton and Shu-Hui
Yen
61. Lewy-like Pathology in Mice Transgenic for Mutant (A53T) and
Wild-type Human a-Synuclein 661
Bernd Sommer, Samuel Barbieri, Katja Hofele, Karl-Heinz Wiederhold,
Alphonse Probst, Claudia Mistl, Simone Danner, Sabine Kauffmann,
Willibrordus Spooren, Markus Tolnay, Graeme Bilbe and Herman van
der Putten
62. Somal and Neuritic Accumulation of the Parkinson’s
Disease-associated Mutant [A30P]a-Synuclein in Transgenic Mice
671
Phillipp J. Kahle, Manuela Neumann, Laurence Ozmen, Hans A.
Kretzschmar and Christian Haass
63. Ex vivo Transmission of Mouse-adapted Prion Strains to N2a
and GT1-7 Cell Lines 679
Sylvain Lehmann, Hubert Laude, David A. Harris, Richard I. Carp,
Didier Vilette, Shigeru Katamine, Jean-Yves Madec and Noriyuki
Nishida
64. In Vivo Perturbation of Lysosomal Function Promotes
Neurodegeneration in the PS1M146V/APPK670N,M671L Mouse Model of
Alzheimer’s Disease Pathology 687
Ralph A. Nixon, Paul M. Mathews, Anne M. Cataldo, Panaiyur S.
Mohan, Stephen D. Schmidt, Karen Duff, Martin Berg, Neville Marks,
Corinne Peterhoff and Henry Sershen
65. Changes in Cognitive Characteristics of Tg(APP)CRND8 Mice at
Early Stages of Immunization with Beta-Amyloid Peptide 697
Christopher Janus, Jacqueline Pearson, Patrick Horne, Richard
Renlund, Karen Parisien, Azhar Chishti, Donna Heslin, Catherine
Bergeron, Paul Fraser, Peter St George-Hyslop and David
Westaway
VI. THERAPEUTICS AND THERAPEUTIC STRATEGIES 705
66. Galantamine, a Novel Treatment for Alzheimer’s Disease: A
Review of Long-term Benefits to Patients and Caregivers 707
Pierre Tariot and Bengt Winblad
67. Benefits of Donepezil on Cognition, Function and
Neuropsychiatric Symptoms in Patients with Mild and Moderate
Alzheimer’s Disease over One Year 725
Gunhild Waldemar, Bengt Winblad, Knut Engedal, Hilkke Soininen,
Frans Verhey, Anders Wimo, Anne-Lena Wetterholm, Richard Zhang,
Anders Haglund, Ponni Subbiah and the Donepezil Nordic Study
Group
68. Characterization of Alzheimer’s b-Secretase Protein BACE:
Processing and Other Post-translational Modifications 739
Mitsuru Haniu, Brian D. Bennett, Paul Denis, Yunjen Young,
Elizabeth A. Mendiaz, Janis Fuller, John O. Hui, Steven Kahn,
Safura Babu-Khan, Sandra Ross, Teresa Burgess, Viswanatham Katta,
Margery Nicolson, Jonathan Lull, Shue-Yuan Wang, Gary Rogers,
Robert Vassar and Martin Citron
69. Androgen Treatment Reduces Cognitive Deficits in Female
apoE4 Transgenic Mice
Jacob Raber, Anthony LeFevour and Lennart Mucke
70. Studies with the Memory-enhancing Drug AIT-082 in PC12 Cells
747
Debomoy K. Lahiri, Yuan-Wen Ge and Martin R. Farlow
71. Generation of Auto-antibodies toward Alzheimer’s Disease
Vaccination 759
Beka Solomon and Dan Frenkel
72. Toward the Identification of c-Secretase: Using Transition
State Analog Inhibitors 777
William P. Esler, W. Taylor Kimberly, Beth L. Ostaszewski, Weiming
Xia, Dennis J. Selkoe and Michael S. Wolfe
73. Photoactivated, Active-site-directed g-Secretase Inhibitors
Covalently Label Presenilin 1 789
Stephen J. Gardell, Yue-Ming Li, Min Xu, Ming-Tain Lai, Qian Huang,
Jose L. Castro, Jillian DiMuzio-Mower, Timothy Harrison, Colin
Lellis, Alan Nadin, Joseph G. Neduvelil, R. Bruce Register,
Mohinder K. Sardana, Mark S. Shearman, Xiao-Ping Shi, Adrian L.
Smith, Kuo-Chang Yin and Jules A. Shafer
74. Functional Analysis of b-Secretase Using Mutagenesis and
Structural Homology Modeling 799
Gwen Tatsuno, John Anderson, Jin Hong, David A. Agard, Nobuyuki
Ota, Sukanto Sinha, Guriqbal Basi and Lisa McConlogue
75. Therapeutic Approaches to Prion Diseases: In Vitro Studies
with Tetracycline Compounds 809
Tazeen Awan, Gianluigi Forloni, Enzio Ragg, Selina Iussich,
Giacomina Rossi, Laura Colombo, Laura Girola, Tania Massignan, Orso
Bugiani, Mario Salmona and Fabrizio Tagliavini
VII. PSYCHOSOCIAL CARE 821
76. Influence of a Memory Training Program on Attention and
Memory Performance of Patients with Dementia 823
Tanja Bernhardt, Konrad Maurer and Lutz Frölich
77. Prediction of Use of Emergency Community Services by
Cognitively Impaired Seniors who Live Alone: Preliminary Findings
of a Prospective Study 833
Mary C. Tierney, Jocelyn Charles, W. Gary Snow, John P. Szalai,
Susan Jaglal, Franca Spizzirri and Rory H. Fisher
Index 835
Khalid Iqbal is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley.
Sangram S. Sisodia is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley.
Bengt Winblad is the editor of Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics, published by Wiley.
"Articles are divided into seven sections on epidemiology and risk factors.... About 400 contributors lend expertise to this professional compendium and contact information is provided for at least one author of every article." (SciTech Book News, Vol. 25, No. 4, December 2001)
![]() |
Ask a Question About this Product More... |
![]() |